Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Summary
Phase 2 clinical trial NCT07552324 registered April 27, 2026, evaluating CL-Pola-R-CHP regimen in patients aged 65 and older with double/triple-hit diffuse large B-cell lymphoma (DHL/THL) who are not suitable for transplantation. The open-label multicenter study employs a 6-cycle treatment with 21-day intervals. This is a study registration entry on ClinicalTrials.gov and does not impose compliance obligations on regulated entities.
“This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
Phase 2 clinical trial NCT07552324 was registered on ClinicalTrials.gov on April 27, 2026, documenting a study of the CL-Pola-R-CHP regimen for double/triple-hit diffuse large B-cell lymphoma (DHL/THL) in patients aged 65 and above who are ineligible for transplantation. The study employs an open-label, multicenter design with 6 treatment cycles repeated every 21 days.
Healthcare providers and clinical investigators should note this as an active Phase 2 enrollment opportunity for elderly lymphoma patients. Pharmaceutical companies developing related agents may track this as competitive landscape information. The registration is informational and does not create regulatory compliance obligations.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Phase 2 NCT07552324 Kind: PHASE2 Apr 27, 2026
Abstract
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Conditions: DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma
Interventions: CL-Pola-R-CHP
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.